TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Treatment for Schizophrenic Smokers
Brief Summary: Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping schizophrenic individuals quit smoking. In addition, this study will evaluate how the combination of bupropion SR and NTP affects psychiatric symptoms and medication side effects.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Varenicline | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Sugar pill
B: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
D: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Treatment for Schizophrenic Smokers
Brief Summary: Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping schizophrenic individuals quit smoking. In addition, this study will evaluate how the combination of bupropion SR and NTP affects psychiatric symptoms and medication side effects.


Options:
A: Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Nicotine gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Bupropion+Nicotine Gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Double placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion, Bupropion+Nicotine Gum, Double placebo, Nicotine gum
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Treatment for Schizophrenic Smokers
Brief Summary: Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping schizophrenic individuals quit smoking. In addition, this study will evaluate how the combination of bupropion SR and NTP affects psychiatric symptoms and medication side effects.


Options:
A: Arm Label: Cohort A; Type: EXPERIMENTAL; Interventions: Procedure: Samples collection, Behavioral: Tobacco and alcohol status follow-up | Arm Label: Cohort B; Type: EXPERIMENTAL; Interventions: Procedure: Samples collection, Behavioral: Psychological and Sociological evaluation, Behavioral: Intensive and sustained smoking cessation program, Behavioral: Tobacco and alcohol status follow-up | Arm Label: Cohort C; Type: EXPERIMENTAL; Interventions: Procedure: Samples collection, Behavioral: Tobacco and alcohol status follow-up | Intervention Type: PROCEDURE; Name: Samples collection; Assigned to Arm(s): Cohort A, Cohort B, Cohort C | Intervention Type: BEHAVIORAL; Name: Psychological and Sociological evaluation; Assigned to Arm(s): Cohort B | Intervention Type: BEHAVIORAL; Name: Intensive and sustained smoking cessation program; Assigned to Arm(s): Cohort B | Intervention Type: BEHAVIORAL; Name: Tobacco and alcohol status follow-up; Assigned to Arm(s): Cohort A, Cohort B, Cohort C
B: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
C: Arm Label: QA-DDS; Type: EXPERIMENTAL; Interventions: Behavioral: QA-DDS | Intervention Type: BEHAVIORAL; Name: QA-DDS; Assigned to Arm(s): QA-DDS
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Trial of Surgery Plus Whole Brain Radiotherapy (WBRT) Versus Radiosurgery Plus WBRT for Solitary Brain Metastases
Brief Summary: This study examines surgery versus radiosurgery (highly focussed radiation) for the treatment of cancer which has spread to one spot in the brain (solitary brain "metastasis"). For these two treatment options, it will compare patients' survival times, quality of life, control rate of the brain metastases and side effects. It uses the most rigorous scientific method available called "randomisation" which minimises biases that exist with other types of studies. It will involve 30 - 40 patients.


Options:
A: Arm Label: Arm I - WBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: whole-brain radiation therapy | Arm Label: Arm II - SRS; Type: EXPERIMENTAL; Interventions: Radiation: stereotactic radiosurgery | Intervention Type: RADIATION; Name: stereotactic radiosurgery; Assigned to Arm(s): Arm II - SRS | Intervention Type: RADIATION; Name: whole-brain radiation therapy; Assigned to Arm(s): Arm I - WBRT
B: Arm Label: Surgery + Whole Brain Radiotherapy; Type: OTHER; Interventions: Procedure: Surgery + WBRT | Arm Label: RadioSurgery + Whole Brain Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Radiosurgery + WBRT | Intervention Type: PROCEDURE; Name: Surgery + WBRT; Assigned to Arm(s): Surgery + Whole Brain Radiotherapy | Intervention Type: RADIATION; Name: Radiosurgery + WBRT; Assigned to Arm(s): RadioSurgery + Whole Brain Radiotherapy
C: Arm Label: Arm I (SRS); Type: EXPERIMENTAL; Interventions: Radiation: Stereotactic Radiosurgery | Arm Label: Arm II (observation); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: RADIATION; Name: Stereotactic Radiosurgery; Assigned to Arm(s): Arm I (SRS)
D: Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: stereotactic radiosurgery; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder
Brief Summary: The purpose of this study is to investigate whether naltrexone reduces the intensity and duration of flashbacks and dissociative states in patients with borderline personality disorder.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: APSOM vs Control | Arm Label: APSOM; Type: OTHER; Interventions: Other: APSOM vs Control | Intervention Type: OTHER; Name: APSOM vs Control; Assigned to Arm(s): APSOM, Control
B: Arm Label: ALGOS group; Type: EXPERIMENTAL; Interventions: Behavioral: ALGOS algorithm of case management | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ALGOS algorithm of case management; Assigned to Arm(s): ALGOS group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 2; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 3; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 4; Type: OTHER; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1, 2, 3, 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder
Brief Summary: The purpose of this study is to investigate whether naltrexone reduces the intensity and duration of flashbacks and dissociative states in patients with borderline personality disorder.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 2; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 3; Type: OTHER; Interventions: Drug: Naltrexone | Arm Label: 4; Type: OTHER; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1, 2, 3, 4
B: Intervention Type: DRUG; Name: Topiramate; Assigned to Arm(s): N/A
C: Arm Label: meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Central Meditation and Imagery Therapy | Arm Label: wait list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Central Meditation and Imagery Therapy; Assigned to Arm(s): meditation
D: Arm Label: General Psychiatric Management (GPM; Gunderson & Links, 2008); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychiatric Management | Arm Label: GPM plus Motive-Oriented Therapeutic Relationship; Type: EXPERIMENTAL; Interventions: Behavioral: Psychiatric Management, Behavioral: Motive-oriented therapeutic relationship/Plan Analysis | Intervention Type: BEHAVIORAL; Name: Psychiatric Management; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship, General Psychiatric Management (GPM; Gunderson & Links, 2008) | Intervention Type: BEHAVIORAL; Name: Motive-oriented therapeutic relationship/Plan Analysis; Assigned to Arm(s): GPM plus Motive-Oriented Therapeutic Relationship

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Omega-3 Fatty Acids in Maintaining Optimal Mental Health in Elderly People: a Double-blind Placebo-controlled Trial
Brief Summary: The efficacy of EPA-DHA supplementation will be assessed in a randomized placebo-controlled trial with cognitive decline and early signs of depression as primary outcome measures.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: EPA omega-3 fatty acid | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA omega-3 fatty acid | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo comparator | Intervention Type: DIETARY_SUPPLEMENT; Name: EPA omega-3 fatty acid; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA omega-3 fatty acid; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo comparator; Assigned to Arm(s): C
B: Arm Label: High Oleic Sunflower Oil; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: n-3 Fatty Acid Supplementation | Arm Label: 400 mg EPA+DHA/day; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: n-3 Fatty Acid Supplementation | Arm Label: 1800 mg EPA+DHA/day; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: n-3 Fatty Acid Supplementation | Intervention Type: BEHAVIORAL; Name: n-3 Fatty Acid Supplementation; Assigned to Arm(s): 1800 mg EPA+DHA/day, 400 mg EPA+DHA/day, High Oleic Sunflower Oil
C: Arm Label: Omega-3 supplement; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplement; Assigned to Arm(s): Omega-3 supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Corn Oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Corn oil | Arm Label: Omega-3 Fatty Acids; Type: EXPERIMENTAL; Interventions: Drug: Omega 3 Fatty Acids | Intervention Type: DRUG; Name: Omega 3 Fatty Acids; Assigned to Arm(s): Omega-3 Fatty Acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn oil; Assigned to Arm(s): Corn Oil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options
Brief Summary: The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects with active RA. Secondary objectives assessed the clinical efficacy of combination treatment, including disease activity, physical function, and quality of life outcomes.


Options:
A: Arm Label: Rituximab Intravenous Infusion; Type: EXPERIMENTAL; Interventions: Drug: Anti-CD20 (rituximab) | Arm Label: Placebo Intravenous Infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Anti-CD20 (rituximab); Assigned to Arm(s): Rituximab Intravenous Infusion | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo Intravenous Infusion
B: Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate
C: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
D: Arm Label: Open-label Abatacept (ABA)-Previous User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Arm Label: Open-label ABA-Current User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Drug: Anti-Tumor Necrosing Factor (TNF) Therapy | Arm Label: Long-term ABA; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD); Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Anti-Tumor Necrosing Factor (TNF) Therapy; Assigned to Arm(s): Open-label ABA-Current User

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever in Eastern Kolkata, West Bengal, India
Brief Summary: This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The purpose of this study is to determine the effectiveness of the Vi vaccine following a mass typhoid immunization campaign in an endemic area in Kolkata, India. The cost-effectiveness of the Vi vaccination and the logistic feasibility of a mass typhoid immunization campaign will also be evaluated.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Typhoid Vi vaccine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Hepatitis A vaccine | Intervention Type: BIOLOGICAL; Name: Typhoid Vi vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Hepatitis A vaccine; Assigned to Arm(s): 2
B: Arm Label: Vi-TCV; Type: EXPERIMENTAL; Interventions: Biological: Vi-TCV | Arm Label: Vi-PS Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vi-PS Vaccine | Arm Label: Control (Men ACWY); Type: OTHER; Interventions: Biological: Control (Men ACWY) | Intervention Type: BIOLOGICAL; Name: Vi-TCV; Assigned to Arm(s): Vi-TCV | Intervention Type: BIOLOGICAL; Name: Vi-PS Vaccine; Assigned to Arm(s): Vi-PS Vaccine | Intervention Type: BIOLOGICAL; Name: Control (Men ACWY); Assigned to Arm(s): Control (Men ACWY)
C: Arm Label: NVGH Vi-CRM197 conjugate vaccine 12.5 mcg; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 12.5 mcg | Arm Label: NVGH Vi-CRM197 conjugate vaccine 5 mcg; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 5.0 mcg | Arm Label: NVGH Vi-CRM197 conjugate vaccine 1.25 mcg; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 1.25 mcg | Arm Label: Typherix; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vi-polysaccharide vaccine | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197 12.5 mcg; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine 12.5 mcg | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197 5.0 mcg; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine 5 mcg | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197 1.25 mcg; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine 1.25 mcg | Intervention Type: BIOLOGICAL; Name: Vi-polysaccharide vaccine; Assigned to Arm(s): Typherix
D: Arm Label: NVGH Vi-CRM197 conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 | Arm Label: Vi-polysaccharide vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Typherix | Intervention Type: BIOLOGICAL; Name: Typherix; Assigned to Arm(s): Vi-polysaccharide vaccine | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet Weight Control for Bingeing Adolescents
Brief Summary: The purpose of this study is to determine if an internet-based intervention designed to reduce binge eating and improve healthy weight regulation skills will result in reductions in binge eating and weight loss, or weight maintenance, in overweight adolescents who binge eat.


Options:
A: Intervention Type: BEHAVIORAL; Name: Internet-based intervention designed to reduce binge eating and improve healthy weight regulation; Assigned to Arm(s): N/A
B: Arm Label: CBT for depression and healthy lifestyle plus exercise; Type: EXPERIMENTAL; Interventions: Behavioral: CBT for depression and healthy lifestyle plus exercise | Arm Label: CBT for depression; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT for depression | Intervention Type: BEHAVIORAL; Name: CBT for depression and healthy lifestyle plus exercise; Assigned to Arm(s): CBT for depression and healthy lifestyle plus exercise | Intervention Type: BEHAVIORAL; Name: CBT for depression; Assigned to Arm(s): CBT for depression
C: Arm Label: Multifaceted intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): Multifaceted intervention
D: Arm Label: Healthy lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy lifestyle managment | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy lifestyle managment; Assigned to Arm(s): Healthy lifestyle intervention

Answer: A